Bristlecone Advisors, LLC Vertex Pharmaceuticals Inc Transaction History
Bristlecone Advisors, LLC
- $1.27 Billion
- Q4 2024
A detailed history of Bristlecone Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Bristlecone Advisors, LLC holds 2,150 shares of VRTX stock, worth $1.05 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
2,150
Previous 2,150
-0.0%
Holding current value
$1.05 Million
Previous $999,000
13.41%
% of portfolio
0.07%
Previous 0.08%
Shares
15 transactions
Others Institutions Holding VRTX
# of Institutions
1,761Shares Held
228MCall Options Held
1.63MPut Options Held
1.47M-
Capital World Investors Los Angeles, CA28.3MShares$13.8 Billion1.8% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.3MShares$11.4 Billion0.17% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10.4 Billion0.23% of portfolio
-
State Street Corp Boston, MA12MShares$5.85 Billion0.2% of portfolio
-
Capital Research Global Investors Los Angeles, CA10.4MShares$5.09 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $125B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...